Mutual Funds that own GTx Inc.
Fidelity Select Biotechnology Portfolio
632,762
2.63%
-20,338
0.17%
07/31/2018
Vanguard Total Stock Market Index Fund
284,344
1.18%
9,712
0%
07/31/2018
Fidelity Advisor Biotechnology Fund
236,468
0.98%
41,362
0.2%
07/31/2018
Federated Kaufmann Small Cap Fund
147,539
0.61%
147,539
0.22%
06/29/2018
Fidelity Select Health Care Portfolio
126,643
0.53%
126,643
0.04%
07/31/2018
Candriam Equities L - Biotechnology
105,000
0.44%
105,000
0.19%
07/31/2018
iShares Russell 2000 ETF
96,432
0.4%
-51
0.01%
09/06/2018
Vanguard Extended Market Index Fund
76,791
0.32%
0
0%
07/31/2018
Fidelity Advisor Health Care Fund
55,802
0.23%
55,802
0.04%
07/31/2018
iShares Russell 2000 Growth ETF
46,483
0.19%
0
0.01%
09/06/2018
| Address |
175 Toyota Plaza
Memphis Tennessee 38103
United States
|
|
Employees
|
- |
| Website |
http://www.gtxinc.com |
| Updated |
09/14/2018 |
| GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. |
